Detection of minimal disease in acute leukemia using flow cytometry: studies in a rat model for human acute leukemia
- PMID: 3860369
- DOI: 10.1002/cyto.990060411
Detection of minimal disease in acute leukemia using flow cytometry: studies in a rat model for human acute leukemia
Abstract
The study was made using a rat model for human acute myelocytic leukemia (BNML), which shows striking similarities with human acute myelocytic leukemia (AML). A monoclonal antibody (MCA-Rm124), raised against BNML cells, allowed the recognition of the leukemic cell fraction. The discriminative capacity of the monoclonal antibody is based on differences in labeling intensities between normal and leukemic cells. After i.v. cellular transfer of leukemia, the growth of the leukemic cell population in the bone marrow, the liver, and the spleen was monitored using MCA-Rm124 and flow cytometry. For the bone marrow and the liver, a clonogenic assay for leukemic cells was used to quantify the cell content in these organs. A good correlation was found between the bioassay-derived data and the flow-cytometry-derived data. The doubling times of the leukemic cell population were not equal for the two organs studied, indicating that a number of different processes contribute to the net cell production per organ. Apart from their application in the detection of residual leukemia, monoclonal antibodies might be employed in the analysis of the growth kinetics of the "invisible" leukemic cell population.
Similar articles
-
Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML).Int J Cell Cloning. 1990 Jan;8(1):27-38. doi: 10.1002/stem.5530080105. Int J Cell Cloning. 1990. PMID: 2403582 Review.
-
Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells.Exp Hematol. 1984 Sep;12(8):667-71. Exp Hematol. 1984. PMID: 6386506
-
[Minimum residual leukemic cells in genetically marked brown Norway rat myelocytic leukemia model].Zhonghua Zhong Liu Za Zhi. 1992 Nov;14(6):414-7. Zhonghua Zhong Liu Za Zhi. 1992. PMID: 1304472 Chinese.
-
The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)).Leukemia. 1990 Apr;4(4):241-57. Leukemia. 1990. PMID: 2195239 Review.
-
A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.Transplantation. 2008 Jan 15;85(1):102-11. doi: 10.1097/01.tp.0000296856.53493.1f. Transplantation. 2008. PMID: 18192919
Cited by
-
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.Best Pract Res Clin Haematol. 2023 Jun;36(2):101468. doi: 10.1016/j.beha.2023.101468. Epub 2023 Apr 18. Best Pract Res Clin Haematol. 2023. PMID: 37353292 Free PMC article. Review.
-
Achieving MRD negativity in AML: how important is this and how do we get there?Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):9-14. doi: 10.1182/hematology.2022000323. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485093 Free PMC article.
-
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?J Clin Med. 2017 Jun 3;6(6):57. doi: 10.3390/jcm6060057. J Clin Med. 2017. PMID: 28587190 Free PMC article. Review.
-
Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats.Cell Prolif. 2000 Dec;33(6):381-95. doi: 10.1046/j.1365-2184.2000.00183.x. Cell Prolif. 2000. PMID: 11101010 Free PMC article.
-
MRD in AML: does it already guide therapy decision-making?Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):356-365. doi: 10.1182/asheducation-2016.1.356. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913502 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical